Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (2): 182-185.DOI: 10.3969/j.issn.1673-8640.2026.02.013
Previous Articles Next Articles
ZHANG Chaomin, YANG Chihui, YI Changlin, LU Wenyuan(
)
Received:2024-08-02
Revised:2025-03-03
Online:2026-02-28
Published:2026-03-06
CLC Number:
ZHANG Chaomin, YANG Chihui, YI Changlin, LU Wenyuan. Human papillomavirus genotype analysis of different cervical lesion patients in Shanghai[J]. Laboratory Medicine, 2026, 41(2): 182-185.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.02.013
| 项目 | 例数 | 6型/% | 11型/% | 16型/% | 18型/% | 26型/% | 31型/% | 33型/% | 35型/% | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCT结果正常 | 3 280 | 2.19 | 1.17 | 7.00 | 2.63 | 0.12 | 3.62 | 2.83 | 1.40 | |||||||||
| CIN Ⅰ | 538 | 2.43 | 1.39 | 9.94 | 2.89 | 0.23 | 3.35 | 3.82 | 2.08 | |||||||||
| CIN Ⅱ | 154 | 0.95 | 0.00 | 30.81 | 2.37 | 0.95 | 4.27 | 3.79 | 0.95 | |||||||||
| CIN Ⅲ | 92 | 0.00 | 0.72 | 31.65 | 2.16 | 0.72 | 5.04 | 8.63 | 0.72 | |||||||||
| SCC | 57 | 0.00 | 0.00 | 40.54 | 13.51 | 1.35 | 2.70 | 4.05 | 0.00 | |||||||||
| 项目 | 39型/% | 42型/% | 43型/% | 44型/% | 45型/% | 51型/% | 52型/% | 53型/% | 56型/% | |||||||||
| TCT结果正常 | 5.00 | 5.60 | 3.78 | 1.96 | 0.88 | 5.62 | 15.82 | 6.03 | 5.23 | |||||||||
| CIN Ⅰ | 4.16 | 4.16 | 2.54 | 0.69 | 1.50 | 5.66 | 15.84 | 4.97 | 6.24 | |||||||||
| CIN Ⅱ | 1.42 | 2.37 | 0.00 | 0.47 | 1.90 | 4.27 | 18.01 | 3.32 | 1.90 | |||||||||
| CIN Ⅲ | 1.44 | 2.88 | 0.72 | 0.00 | 1.44 | 1.44 | 15.11 | 3.60 | 2.88 | |||||||||
| SCC | 2.70 | 0.00 | 0.00 | 0.00 | 0.00 | 2.70 | 12.16 | 0.00 | 1.35 | |||||||||
| 项目 | 58型/% | 59型/% | 66型/% | 68型/% | 73型/% | 81型/% | 82型/% | 83型/% | ||||||||||
| TCT结果正常 | 8.87 | 3.11 | 3.64 | 4.72 | 0.58 | 6.52 | 1.34 | 0.37 | ||||||||||
| CIN Ⅰ | 9.60 | 3.82 | 5.78 | 3.35 | 0.69 | 4.05 | 0.58 | 0.23 | ||||||||||
| CIN Ⅱ | 14.22 | 0.00 | 3.32 | 2.37 | 0.00 | 1.42 | 0.47 | 0.47 | ||||||||||
| CIN Ⅲ | 12.23 | 0.72 | 0.00 | 5.76 | 0.72 | 1.44 | 0.00 | 0.00 | ||||||||||
| SCC | 13.51 | 1.35 | 0.00 | 0.00 | 0.00 | 4.05 | 0.00 | 0.00 | ||||||||||
| 项目 | 例数 | 6型/% | 11型/% | 16型/% | 18型/% | 26型/% | 31型/% | 33型/% | 35型/% | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCT结果正常 | 3 280 | 2.19 | 1.17 | 7.00 | 2.63 | 0.12 | 3.62 | 2.83 | 1.40 | |||||||||
| CIN Ⅰ | 538 | 2.43 | 1.39 | 9.94 | 2.89 | 0.23 | 3.35 | 3.82 | 2.08 | |||||||||
| CIN Ⅱ | 154 | 0.95 | 0.00 | 30.81 | 2.37 | 0.95 | 4.27 | 3.79 | 0.95 | |||||||||
| CIN Ⅲ | 92 | 0.00 | 0.72 | 31.65 | 2.16 | 0.72 | 5.04 | 8.63 | 0.72 | |||||||||
| SCC | 57 | 0.00 | 0.00 | 40.54 | 13.51 | 1.35 | 2.70 | 4.05 | 0.00 | |||||||||
| 项目 | 39型/% | 42型/% | 43型/% | 44型/% | 45型/% | 51型/% | 52型/% | 53型/% | 56型/% | |||||||||
| TCT结果正常 | 5.00 | 5.60 | 3.78 | 1.96 | 0.88 | 5.62 | 15.82 | 6.03 | 5.23 | |||||||||
| CIN Ⅰ | 4.16 | 4.16 | 2.54 | 0.69 | 1.50 | 5.66 | 15.84 | 4.97 | 6.24 | |||||||||
| CIN Ⅱ | 1.42 | 2.37 | 0.00 | 0.47 | 1.90 | 4.27 | 18.01 | 3.32 | 1.90 | |||||||||
| CIN Ⅲ | 1.44 | 2.88 | 0.72 | 0.00 | 1.44 | 1.44 | 15.11 | 3.60 | 2.88 | |||||||||
| SCC | 2.70 | 0.00 | 0.00 | 0.00 | 0.00 | 2.70 | 12.16 | 0.00 | 1.35 | |||||||||
| 项目 | 58型/% | 59型/% | 66型/% | 68型/% | 73型/% | 81型/% | 82型/% | 83型/% | ||||||||||
| TCT结果正常 | 8.87 | 3.11 | 3.64 | 4.72 | 0.58 | 6.52 | 1.34 | 0.37 | ||||||||||
| CIN Ⅰ | 9.60 | 3.82 | 5.78 | 3.35 | 0.69 | 4.05 | 0.58 | 0.23 | ||||||||||
| CIN Ⅱ | 14.22 | 0.00 | 3.32 | 2.37 | 0.00 | 1.42 | 0.47 | 0.47 | ||||||||||
| CIN Ⅲ | 12.23 | 0.72 | 0.00 | 5.76 | 0.72 | 1.44 | 0.00 | 0.00 | ||||||||||
| SCC | 13.51 | 1.35 | 0.00 | 0.00 | 0.00 | 4.05 | 0.00 | 0.00 | ||||||||||
| 项目 | 例数 | 单一型别 感染/ % | 多重感染/ % | 感染2个 型别/ % | 感染3个 型别/ % | 感染4个 型别/ % | 感染5个 型别/ % | 感染6个 型别/ % | 感染7个 型别/ % |
|---|---|---|---|---|---|---|---|---|---|
| TCT结果正常 | 3 280 | 76.52 | 23.48 | 17.56 | 3.90 | 1.31 | 0.52 | 0.09 | 0.09 |
| CIN Ⅰ级 | 538 | 59.48 | 40.52 | 27.32 | 8.92 | 2.60 | 0.93 | 0.37 | 0.37 |
| CIN Ⅱ级 | 154 | 74.03 | 25.97 | 17.53 | 5.84 | 2.60 | 0.00 | 0.00 | 0.00 |
| CIN Ⅲ级 | 92 | 64.13 | 35.87 | 22.83 | 10.87 | 2.17 | 0.00 | 0.00 | 0.00 |
| SCC | 57 | 77.19 | 22.81 | 19.30 | 1.75 | 0.00 | 1.75 | 0.00 | 0.00 |
| 项目 | 例数 | 单一型别 感染/ % | 多重感染/ % | 感染2个 型别/ % | 感染3个 型别/ % | 感染4个 型别/ % | 感染5个 型别/ % | 感染6个 型别/ % | 感染7个 型别/ % |
|---|---|---|---|---|---|---|---|---|---|
| TCT结果正常 | 3 280 | 76.52 | 23.48 | 17.56 | 3.90 | 1.31 | 0.52 | 0.09 | 0.09 |
| CIN Ⅰ级 | 538 | 59.48 | 40.52 | 27.32 | 8.92 | 2.60 | 0.93 | 0.37 | 0.37 |
| CIN Ⅱ级 | 154 | 74.03 | 25.97 | 17.53 | 5.84 | 2.60 | 0.00 | 0.00 | 0.00 |
| CIN Ⅲ级 | 92 | 64.13 | 35.87 | 22.83 | 10.87 | 2.17 | 0.00 | 0.00 | 0.00 |
| SCC | 57 | 77.19 | 22.81 | 19.30 | 1.75 | 0.00 | 1.75 | 0.00 | 0.00 |
| 项目 | 例数 | 低危型HPV/% | 高危型HPV/% |
|---|---|---|---|
| TCT结果正常 | 3 280 | 21.58 | 78.42 |
| CIN Ⅰ级 | 538 | 15.49 | 84.51 |
| CIN Ⅱ级 | 154 | 5.69 | 94.31 |
| CIN Ⅲ级 | 92 | 5.76 | 94.24 |
| SCC | 57 | 4.05 | 95.95 |
| 项目 | 例数 | 低危型HPV/% | 高危型HPV/% |
|---|---|---|---|
| TCT结果正常 | 3 280 | 21.58 | 78.42 |
| CIN Ⅰ级 | 538 | 15.49 | 84.51 |
| CIN Ⅱ级 | 154 | 5.69 | 94.31 |
| CIN Ⅲ级 | 92 | 5.76 | 94.24 |
| SCC | 57 | 4.05 | 95.95 |
| [1] | 石明芳, 曾江辉, 周元圆, 等. 24 158例人乳头瘤病毒基因检测结果分析[J]. 医学检验与临床, 2024, 35(4):5-8. |
| [2] |
HAN M, LI J, AUSTIN M, et al. Human papillomavirus (HPV) 16 and 18/45 genotyping-directed follow-up of women with messenger RNA HPV-positive,cytology-negative cervical screening test results[J]. Am J Clin Pathol, 2020, 153(2):243-250.
DOI URL |
| [3] |
CHARAKORN C, THADANIPON K, CHAIJINDARATANA S, et al. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma:a systematic review and meta-analysis[J]. Gynecol Oncol, 2018, 150(1):190-200.
DOI URL |
| [4] | ZHANG J, QIN L, CHEN H M, et al. Overall survival,locoregional recurrence,and distant metastasis of definitive concurrent chemoradiotherapy for cervical squamous cell carcinoma and adenocarcinoma:before and after propensity score matching analysis of a cohort study[J]. Am J Cancer Res, 2020, 10(6):1808-1820. |
| [5] |
LI X, XU C, YU Y, et al. Prediction of lymphovascular space invasion using a combination of tenascin-C,cox-2,and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma[J]. BMC Cancer, 2021, 21:866.
DOI |
| [6] | 国家卫生健康委员会. 宫颈癌诊疗指南[S]. 北京: 人民卫生出版社, 2022. |
| [7] |
ZHANG J, CHENG K, WANG Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China:a meta-analysis[J]. Arch Gynecol Obstet, 2020, 302(6):1329-1337.
DOI |
| [8] |
LI J, GAO J J, LI N, et al. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions[J]. Arch Virol, 2021, 166(3):853-862.
DOI PMID |
| [9] |
GUO C, DU H, BELINSON J L, et al. The prevalence and distribution of human papillomavirus among 10 867 Chinese Han women[J]. Infect Agent Cancer, 2021, 16(1):21.
DOI |
| [10] | LIU J, MA S, QIN C, et al. Prevalence and genotype distribution of human papillomavirus in Zhengzhou,China,in 2016[J]. Arch Virol, 2020, 165(3):731-736. |
| [11] |
WEI F, GEORGES D, MAN I, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide:a systematic analysis of the global literature[J]. Lancet, 2024, 404(10451):435-444.
DOI URL |
| [12] |
YUAN Y, CAI X, SHEN F, et al. HPV post-infection microenvironment and cervical cancer[J]. Cancer Lett, 2021, 497:243-254.
DOI PMID |
| [13] |
LEI J, PLONER A, ELFSTRÖM K M, et al. HPV vaccination and the risk of invasive cervical cancer[J]. N Engl J Med, 2020, 383(14):1340-1348.
DOI URL |
| [14] |
IBRAGIMOVA M, TSYGANOV M, SHPILEVA O, et al. HPV status and its genomic integration affect survival of patients with cervical cancer[J]. Neoplasma, 2018, 65(3):441-448.
DOI PMID |
| [15] | 徐露露, 张琴, 孙梅. HPV感染型别及多重感染与女性宫颈病变的关联性分析[J]. 蚌埠医学院学报, 2023, 48(5):637-640. |
| [16] | STROHL A E, MENDOZA G, GHANT M S, et al. Barriers to prevention:knowledge of HPV,cervical cancer,and HPV vaccinations among African American women[J]. Am J Obstet Gynecol, 2015, 212(1):65.e1-65.e5. |
| [1] | ZHOU Chaoqiong, CHEN Ting, KONG Lirui, MA Chunyu. Clinical role of gene mutation types and MCV,MCH levels in patients with thalassemia in Pidu District of Chengdu City [J]. Laboratory Medicine, 2026, 41(1): 52-57. |
| [2] | CAO Yue, SUN Qijuan, WANG Su, PAN Yiru, WANG Shiwen. Reference range of serum cystatin C in elders in Shanghai [J]. Laboratory Medicine, 2025, 40(8): 731-734. |
| [3] | BAO Yun, YU Tingting, QUAN Jing, YIN Liufan, ZHANG Pengyin, XIAO Yanqun. Result analysis of external quality assessment of next-generation sequencing for genetic testing of inherited diseases in Shanghai [J]. Laboratory Medicine, 2025, 40(2): 160-164. |
| [4] | LIU Xiaowen, SHAO Wenqi, ZHU Jing, YANG Jing, ZHANG Chunyan, PAN Baishen, WANG Beili, GUO Wei. Establishment of reference interval of serum ferritin in adults in Shanghai by indirect method [J]. Laboratory Medicine, 2024, 39(6): 524-529. |
| [5] | ZHAO Yanan, XIAO Weili, CAO Qixin, YAN Yan, CUI Xiuge, ZHAO Jianping. Relation of drug resistance,serotypes and genotypes of Group B Streptococcus in perinatal pregnant females and pregnancy outcomes [J]. Laboratory Medicine, 2024, 39(4): 382-386. |
| [6] | WANG Zhengquan, WU Zhengmu, LI Wen. Long-term biological variation of serum sex hormones during female follicular phase in Shanghai [J]. Laboratory Medicine, 2024, 39(3): 282-288. |
| [7] | ZHU Jieke, ZHOU Peng, LUO Ying, WU Maofeng, XUAN Shuxia, CHEN Chen, QI Huaxin, OUYANG Yu, YIN Weiguo. Correlation of HPV combined with lower genital tract pathogen infection and cervical lesion [J]. Laboratory Medicine, 2024, 39(11): 1097-1100. |
| [8] | ZHANG Yaxu, CUI Yanwei, LIU Ziyan. Preliminary research for the determination of HPV E6/E7 mRNA by nucleic acid molecular hybridization-flow cytometry [J]. Laboratory Medicine, 2023, 38(1): 46-50. |
| [9] | LI Keke, XIAO Yang. Research progress of coagulation factor Ⅴ and its association with hemorrhage and thrombosis [J]. Laboratory Medicine, 2022, 37(4): 396-399. |
| [10] | YANG Xue, JU Yi, OU Yuanzhu, ZHU Yuqing, XU Chong, JIANG Lingli, WANG Qing, ZHOU Jing. Analysis on the results of external quality assessment of mutual recognition quantitative items in Shanghai [J]. Laboratory Medicine, 2022, 37(12): 1129-1134. |
| [11] | WANG Jingjing, WU Linqing, CHEN Rushou, WANG Yufeng. Drug resistance genotype,transposon structure and MLSA of vancomycin-resistant Enterococcus [J]. Laboratory Medicine, 2021, 36(9): 891-895. |
| [12] | FANG Zhongjun, JI Weiqing, ZHANG Jingxian, WU Jintao, WU Weihua, JIANG Ying, HAN Zhenge, HE Dongyi, BIAN Yanqin, SHEN Yu, XIAO Lianbo, XIE Donghao, SUN Yang. HLA-B*5801 gene carrying rate and laboratory testing indicators in patients with gouty arthritis [J]. Laboratory Medicine, 2021, 36(9): 896-900. |
| [13] | JIAO Ruibao, TANG Jibin, ZHOU Jiali, ZHU Juanjuan, CHEN Jizhong. Genotype polymorphism distribution of GPⅠa G873A and C807T in cardio-cerebrovascular disease and diabetes mellitus [J]. Laboratory Medicine, 2021, 36(6): 581-585. |
| [14] | GU Yuwei, WANG Chengyun, GU Ping, PAN Qiuhui, WANG Jing, CHEN Guangjie. Weak expression of antigen caused by the variation in the regulatory region of ABO allele and cause analysis [J]. Laboratory Medicine, 2021, 36(6): 637-641. |
| [15] | LIU Hongqian, SONG Chaohui, LIANG Qiaomi. Determination and quantitation of blood human papillomavirus DNA in healthy subjects [J]. Laboratory Medicine, 2021, 36(11): 1121-1124. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||